-
2022-500536-11-00
5
Moderately to severely active ulcerative colitis
-
2022-500537-84-00
5
Moderately to severely active ulcerative colitis
-
2025-521371-31-00
4
Sepsis
-
2025-521590-13-00
5
2026-05-28
Moderately to Severely Active Crohn’s Disease
-
2025-521903-28-00
5
2026-05-06
Adenovirus viremia
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518006-40-00
5
2025-11-13
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
-
2025-523461-17-01
5
2026-06-01
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-522007-18-00
5
2026-05-27
Relapsed or Refractory Multiple Myeloma
-
2025-521108-23-00
5
2026-05-19
Chronic Obstructive Pulmonary Disease
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2023-505834-84-00
10
2025-06-17
relapsed and refractory primary diffuse large B-cell lymphoma of the C
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2023-507660-39-00
5
2024-12-03
Myotonic dystrophy type 1 (DM1)
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-508614-41-00
4
2024-10-15
The study will be proposed to all adult patients receiving an allogene
-
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease